Moleculera BiosciencesIn The News
October 1, 2024
BioSymetrics and Moleculera Partner to Advance Personalized Treatment for Immune-mediated Neuropsychiatric Disorders
Alliance will leverage BioSymetrics' Elion Platform and Moleculera’s expansive biorepository and database to develop advanced predictive treatment algorithms
September 10, 2024
Moleculera Biosciences welcomes Asad Hussain as Board Advisor on Strategic Finance
Appointment will help company drive financial performance, enhance operational efficiencies, and support long-term growth objectives
AUGUST 22, 2024
Moleculera Biosciences Names B. Robert Mozayeni, MD as Medical and Clinical Advisor
Appointment will provide strategic guidance and insights as the company expands scope of work for immune-mediated disorders
JULY 30, 2024
Moleculera Labs announces rebrand to Moleculera Biosciences as company expands into new sectors
Rebrand aligns with precision medicine messaging for growth and expansion into additional immune-mediated disorder markets
JULY 10, 2024
Moleculera Biosciences Names Dr. Safedin Sajo Beqaj as Clinical Laboratory Advisor
Appointment strengthens Company's Scientific and Clinical Board of Advisors as it continues to expand scope of its personalized medicine business
MAY 23, 2024
Moleculera Biosciences Board of Directors names Healthcare Innovator and Leader Dr. Vijay Aggarwal as Board Chair
Newly appointed Chairman of the Board will provide strategic guidance and enhanced governance and value creation for Moleculera Biosciences
JANUARY 17, 2024
Moleculera Labs Forms Strategic Collaboration with Quest Diagnostics
Companies Collaborate to Broaden Access to Moleculera’s Novel Neuropsychiatric Autoantibody Testing
JANUARY 11, 2024
Moleculera Labs, Inc., Awarded $500,000 Grant Funding to Develop Predictive Treatment Algorithm
Company leveraging strategic alliance w/OKC-based General Genomics to build next-gen predictive treatment model for immune-mediated neuropsychiatric disorders
JANUARY 03, 2024
Moleculera Labs Names Healthcare Industry Veteran Rodney Cotton to Board of Directors
Company readies for growth and expansion of its business to identify and improve chronic immune-mediated disorders
JULY 26, 2022
Moleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders
GGI will bring the power of multiple patent-pending healthcare machine learning (ML) and artificial intelligence (AI) innovations to direct individualized healthcare. Moleculera will contribute its knowledge and expertise in autoimmune neuropsychiatric disorders.
JANUARY 08, 2020
Moleculera Labs’ Study Demonstrates Clinical Utility and Accuracy of the Cunningham Panel™ in Patients With Symptoms of Autoimmune Encephalopathy
Positive correlation seen between the Cunningham Panel assay results and patients’ neuropsychiatric symptoms
MARCH 27, 2019
U.S. Patent Office Expands Patent Protection for Moleculera Labs’ Diagnostic Panel for Neuropsychiatric Disorders
Cunningham Panel™ Helps Physicians Diagnose Autoimmune-Related Neuropsychiatric Conditions including PANS/PANDAS
SEPTEMBER 12, 2018
Intravenous Immunoglobulin (IVIg) Treatment May Benefit Some Children with Autism Spectrum Disorder
Biomarkers included on Moleculera Labs’ Cunningham Panel™ shown to be helpful in identifying a subset of autistic children likely to benefit from IVIg therapy
NOVEMBER 6, 2017
Moleculera Labs Issued Key U.S. Patent Covering the Company’s Diagnostic Panel for Infection-Induced Autoimmune Neuropsychiatric Disorders
Understanding of PANS/PANDAS Gained via Moleculera’s Cunningham Panel™ May Provide Model for Understanding and Treating Other Chronic Neuropsychiatric Disorders in Adults
JANUARY 20, 2016
Moleculera Labs Highlights Biomarker-Based Tests as Diagnostic Aid for Infection-Triggered CNS Disorders
Company to Present at 2016 Personalized Medicine World Congress
JULY 30, 2015
Infection-Triggered Autoimmune Attacks on the Brain Underlie Some Sudden Onset Neuropsychiatric Illnesses, Says Moleculera Labs Chief Scientific Officer
International OCD Foundation Conference to feature discussion of causes, diagnosis and treatment of PANS and PANDAS
JULY 7, 2015
Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin
This grant supports the development and clinical validation of new diagnostic testing panels to identify autoantibodies directed against neuronal antigens in patients.
APRIL 23, 2013
Innovator of the Year: Moleculera Labs wins overall award
Oklahoma City-based Moleculera Labs received the overall award for its testing of children suffering from forms of neurologic disorders associated with autoimmunity.